Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapyDeborah H. Charych, Jonathan Zalevsky, Samira Khalili et al.|PLoS ONE|2017Cited by 145
NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseasesNeha Dixit, Jonathan Zalevsky, Christie Fanton et al.|Journal of Translational Autoimmunity|2021Cited by 54
Immune memory in nonclinical models after treatment with NKTR-214, an engineered cytokine biased towards expansion of CD8+ T cells in tumor.Deborah H. Charych, Jonathan Zalevsky, Werner Rubas et al.|Journal of Clinical Oncology|2016Cited by 1
Combining complementary mechanisms of immune activation: NKTR-214, a biased IL-2 pathway agonist and immune checkpoint antagonistsDeborah H. Charych, Jonathan Zalevsky, Murali K. Addepalli et al.|Annals of Oncology|2016Cited by 0
Abstract 1617: Mechanistic modeling of a new kinetically-controlled CD122 agonist for cancer immunotherapy: NKTR-214 pharmacokinetics, pharmacodynamics, and receptor pharmacologySamira Khalili, Ute Hoch, Aleksandrs Odinecs et al.|Cancer Research|2017Cited by 0